Moderna is dropping an IL-2 program in autoimmune disorders after AstraZeneca returned the rights, the mRNA leader announced Thursday in its third quarter filing.
https://www.pharmalive.com/wp-content/uploads/2021/12/In-Head-to-Head-Comparison-Moderna-Bests-Pfizer-by-a-Nose-BioSpace-12-3-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-03 11:18:292022-11-03 11:18:29Moderna loses AstraZeneca's support in IL-2 program, must defend Arbutus suit
